Activist investor Bill Ackman broke all of his personal investment rules when he bet big on Valeant Pharmaceuticals. And now he’s calling the move “one very big mistake.”
As the Pershing Square Capital Management chief told CNBC’s “Squawk Box,” he “went off the reservation” with the Canadian drugmaker.
“We never normally get to meet the management of a company before making an investment. [And] we never invest in really complicated companies you can’t figure out from just reading the 10-K [filing],” he said.
But those standards went out the window when Ackman and then-Valeant head honcho J. Michael Pearson joined forces to make a hostile play for Allergan in 2014, and Ackman continued to up his Valeant stake even in the wake of the buyout quest’s failure.
Of course, Valeant has since come crashing down, thanks to channel-stuffing allegations, pricing pushback and debt-default concerns–and Ackman has paid the price. He called the past 12 months the “worst period of performance” of his investment career, placing the blame squarely on Valeant’s downward spiral.
Those who played large roles in advising Ackman to take a chance on the Quebec-based drugmaker? They’ve paid it, too. Friday, Ackman said analyst Jordan Rubin–the last remaining player who had worked closely on the investment–was set to depart Pershing Square, Reuters reported.
Ackman, though, is still doing what he can to right the ship, and toward that end, he took on a more active role this March when he assumed a director position on Valeant’s board. And with a handful of changes already made to the company’s leadership–including the hiring of new CEO Joseph Papa, formerly the skipper at Perrigo, and of CFO Paul Herendeen, a Zoetis veteran–he thinks the company is in better shape than it was.
At the very least, Valeant now looks like a “more traditional Pershing Square investment” now that it’s taken a beating, he said.
“We normally invest when shareholders have lost confidence in management,” he told CNBC. “And that’s what happened here.”
By Carly Helfand
Source: Fierce Pharma
Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.
Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.
US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
